Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

Prostate Cancer and Prostatic Diseases volume 9, pages 14–18 (2006)Cite this article

Abstract

Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this article is to review the evidence for such a link.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Morales A, Lunenfeld B . Investigation, treatment and monitoring of late-onset hypogonadism. The Aging Male 2002; 5: 74–86.

    Article  CAS  Google Scholar 

  2. Vermeulen A, Kaufman JM . Ageing of the hypothalamo-pituitary-gonadal axis in men. Horm Res 1995; 43: 25–28.

    Article  CAS  Google Scholar 

  3. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239.

    Article  CAS  Google Scholar 

  4. World Health Organisation. Guidelines for the Use of Androgens in Men. Geneva, 1992.

  5. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer L Clin 2004; 54: 8–29.

    Article  Google Scholar 

  6. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371–2490.

    Article  CAS  Google Scholar 

  7. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B et al. Latent carcinoma of the prostate at autopsy in seven areas. The International Agency for research in Cancer; Lyons, France. Int J Cancer 1977; 20: 680–688.

    Article  CAS  Google Scholar 

  8. Lichtenstein P, Holm NV, Verkasalo PK . Environmental and inheritable factors in the causation of cancer. N Engl J Med 2002; 343: 78–85.

    Article  Google Scholar 

  9. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB . The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6–12.

    Article  CAS  Google Scholar 

  10. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R et al. GTSP1 CpG island hypermethylation is responsible for the absence of GTSP1 expression in human prostate cancer cells. Am J Pathol 2001; 159: 1825–1826.

    Google Scholar 

  11. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL . Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to prostate cancer evolution? J Urol 2005; 173: 1969–1974.

    Article  Google Scholar 

  12. Hoffman MA, DeWolf WC, Morgentaler A . Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824–827.

    Article  CAS  Google Scholar 

  13. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449–453.

    Article  CAS  Google Scholar 

  14. Maderbacher S, Schalzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P et al. Impact of radical prostatectomy and TURP on the hypothalamo-pituitary-gonadal hormone axis. Urology 2002; 60: 869–874.

    Article  Google Scholar 

  15. Krieg M, Nass R, Tunn S . Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993; 77: 375–381.

    CAS  PubMed  Google Scholar 

  16. Slater S, Oliver RTD . Testosterone: its role in the development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 431–439.

    Article  CAS  Google Scholar 

  17. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995; 27: 25–31.

    Article  CAS  Google Scholar 

  18. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanem A et al. Serum testosterone and sex hormone binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999; 86: 312–315.

    Article  CAS  Google Scholar 

  19. Hsing AW . Hormones and prostate cancer: what's next? Epidemiol Rev 2001; 23: 42–58.

    Article  CAS  Google Scholar 

  20. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS . Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 847–853.

    Article  CAS  Google Scholar 

  21. Morgentaler A, Bruning III CO, DeWolf WC . Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904–1906.

    Article  CAS  Google Scholar 

  22. Thompson IM, Goodman PJ, Yangen CM . The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 21–24.

    Article  Google Scholar 

  23. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314–1317.

    Article  CAS  Google Scholar 

  24. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S . Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179–2184.

    Article  CAS  Google Scholar 

  25. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS . Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. J Urol 2004; 64: 537–541.

    Article  CAS  Google Scholar 

  26. Giovannucci E, Stampfer MJ, Krithivsa K, Brown M, Dahl D, Brufsky A et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320.

    Article  CAS  Google Scholar 

  27. Chamberlain NL, Driver ED, Miesfeld RL . The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 3181.

    Article  CAS  Google Scholar 

  28. Tenover JS . Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098.

    CAS  PubMed  Google Scholar 

  29. Hajjar RR, Kaiser FE, Morley JE . Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–3796.

    Article  CAS  Google Scholar 

  30. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA . Pharmacokinetics, efficacy and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469–3478.

    CAS  PubMed  Google Scholar 

  31. Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C . Testosterone replacement in older hypogonadal men: a 12-month randomised controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667.

    Article  CAS  Google Scholar 

  32. Guay AT, Perez JB, Fitaihi WA, Vereb M . Testosterone treatment in hypogonadal men: prostate specific antigen level and risk of prostate cancer. Endocrin Pract 2000; 6: 132–138.

    Article  CAS  Google Scholar 

  33. Svetec DA, Canby ED, Thomson IM, Sabanegh Jr ES . The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997; 158: 1775–1777.

    Article  CAS  Google Scholar 

  34. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG . Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerentol A Biol Sci Med Sci 2001; 56: M266–M272.

    Article  CAS  Google Scholar 

  35. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839–2853.

    CAS  PubMed  Google Scholar 

  36. Gooren LJ . A ten-year safety study of oral androgen testosterone undecanoate. J Androl 1994; 15: 212–215.

    CAS  PubMed  Google Scholar 

  37. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD . Prostate specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922–926.

    PubMed  Google Scholar 

  38. Snyder PJ, Peachey H, Hannoush P, Loh L, Holmes JH, Dlewati A et al. Effect of testosterone on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972.

    CAS  PubMed  Google Scholar 

  39. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al. Effets of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–2677.

    CAS  PubMed  Google Scholar 

  40. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel treatment maintains beneficial effects on sexual function and mood, lean and fat mass and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098.

    Article  CAS  Google Scholar 

  41. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429–5434.

    Article  CAS  Google Scholar 

  42. Feneley MR, Carruthers M . PSA monitoring during testosterone replacement therapy: low long-term risk of prostate cancer with improved opportunity for cure. Andrologia 2004; 36: 212.

    Google Scholar 

  43. Rhoden EL, Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk of prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170: 2348–2351.

    Article  CAS  Google Scholar 

  44. Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004; 10: 2231–2236.

    Article  Google Scholar 

  45. Liverman CT, Blazer DG (eds). Testosterone and Aging: Clinical Research Directions. Institute of Medicine of the National Academies Press: Washington DC, 2004.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Prostate Centre, Wimpole Street, London, UK

    D C Gould & R S Kirby

Authors
  1. D C Gould
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R S Kirby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D C Gould.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gould, D., Kirby, R. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?. Prostate Cancer Prostatic Dis 9, 14–18 (2006). https://doi.org/10.1038/sj.pcan.4500839

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500839

Keywords

This article is cited by

Search

Advanced search

Quick links